Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06119685 · ClinicalTrials.gov registry record · Phase 1
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
A Phase 1 study of Multiple Myeloma and Refractory Multiple Myeloma, sponsored by Indapta Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 128
- Enrollment target
- 12
- Study locations
NCT06119685 is a Phase 1 study of Multiple Myeloma and Refractory Multiple Myeloma that is actively recruiting participants, run by Indapta Therapeutics. The registered enrollment target is 128 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (77% lower). The trial reports 12 study locations across 12 states.
The verdict
NCT06119685, a Phase 1 study of Multiple Myeloma and Refractory Multiple Myeloma, is actively recruiting participants, sponsored by Indapta Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 128 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and preliminary antitumor activity in patients with advanced hematologic cancers.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Rituximab
- DRUG Daratumumab
- DRUG Interleukin-2
- DRUG IDP-023
Study Locations (12)
California
- Valkyrie Clinical Trials - Los Angeles
Florida
- Florida Cancer Specialists and Research Institute - Lake Mary Cancer Center - Lake Mary
Georgia
- Emory University Hospital - Atlanta
Minnesota
- University of Minnesota - Minneapolis
New York
- NYP/Weill Cornell Medical Center - New York
North Carolina
- Atrium Health Wake Forest Baptist - Winston-Salem
Ohio
- University Hospitals Cleveland - Cleveland
Oregon
- Providence Cancer Institute Franz Clinic - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2023-10-25 |
| Est. Completion | 2029-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06119685
The ClinicalTrials.gov registry entry for NCT06119685 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (77% lower). The listed sponsor is Indapta Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT06119685 reports 12 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT06119685 about?
NCT06119685 is a clinical study titled "IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers". This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and pre...
What is the current status of trial NCT06119685?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 128 participants. The study started on 2023-10-25. Estimated completion is 2029-12-31.
What conditions does trial NCT06119685 study?
This clinical trial studies the following conditions: Multiple Myeloma, Refractory Multiple Myeloma, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Blood Cancer.
What interventions are being tested in trial NCT06119685?
The interventions under investigation include: Cyclophosphamide (DRUG), Rituximab (DRUG), Daratumumab (DRUG), Interleukin-2 (DRUG), IDP-023 (DRUG).
Who is sponsoring clinical trial NCT06119685?
This trial is sponsored by Indapta Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06119685 being conducted?
This trial has 12 study locations across California, Florida, Georgia, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.